3[5]Kornhuber J,Weller M,Schoppmeyer K,et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties [J].J Neural Transm, 1994,43 ( Suppl ) :91.
4[6]Victor Daryl,Waters Cheryl. Monoamine oxidase inhibitors in Parkinson's disease[J].Neurological Disease and Therapy,2003,59(Handbook of Parkinson's disease( 3rd Edition) ):425.
5邓安春.治疗帕金森病的一线药物普拉克索[J].国外医学·药学分册,2002,(3):180.
6[10]William CK.Levodopa in the treatment of PD[J].Neurology,2000,55(suppl 4) :2.
7[11]Katzenschlager Regina, Lees Andrew J.Treatment of Parkinson's disease:levodopa as the first choice [J].Neurology,2002,249( Suppl 2 ): 19.
8[12]Poewe W.Recent advances in the drug treatment of Parkinson's disease[J]. Curop in Neurol, 1999,12 ( 4 ) :411.
9[15]Tabakman R,Lecht S,Lazarovici P. Neuroprotection by monoamine oxidase B inhibitors:a therapeutic strategy for Parkinson's disease[J].Bio Essays,2004,26( 1 ) :80.
10[16]Rabey JM,Sagi I,Huberman M,et al.Rasagiline mesylate,a new MAO-B inhibitor for the treatment of Parkinson's disease:A double-blind study as adjunctive therapy to levodopa[J].Clinical Neuropharmacology, 2000,23 ( 6 ): 324.
